Efficacy of psychostimulant drugs for cocaine dependence

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Castells, Xavier ^a   Casas, Miguel ^a   Bosch, Rosa ^a   Ramos Quiroga, Josep Antoni ^a   Roncero, Carlos ^a   Vidal, Xavier ^a   Capellà, Dolors ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Fundacion Institut Catala de Farmacologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; COCAINE; MUSCLE RELAXANT AGENT; NOOTROPIC AGENT; PSYCHOSTIMULANT AGENT; SELEGILINE; XANTHINE DERIVATIVE;

CLINICAL PROTOCOL; COCAINE DEPENDENCE; COMORBIDITY; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; REVIEW; SYSTEMATIC REVIEW;

EID: 55049106108     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007380     Document Type: Review

References (22)

1. Castells 2007 Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga JA, Capellà D. Efficacy of central nervous systemstimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomised controlled clinical trials. Addiction 2007;1002:1871- 87.
2. Dole 1969 Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969;280:1372-5.
3. DSM IV American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.. 4 edition. American Psychiatric Publishing, 2000.
4. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
5. EMCDDA 2007a European Monitoring Center for Drugs and Drug Addition. COCAINE AND CRACK COCAINE:A GROWING PUBLIC HEALTH ISSUE. http://www.emcdda.europa.eu/attachements.cfm/att_41643_EN_dummypdf.pdf 2007.
6. EMCDDA 2007b European Monitoring Center for Drugs and Drug Addition. The state of the drugs problem in Europe. http://www.emcdda.europa.eu/ html.cfm/index1308EN.html 2007.
7. Gorelick 2004 Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs 2004;64:1547-73.
8. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.
9. Kalivas 2005 Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-13.
10. Kidorf 1993 Kidorf M, Stitzer ML. Descriptive analysis of cocaine use of methadone patients. Drug Alcohol Depend 1993;32:267-75.
11. Kleber 2007 Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfield SF, Kosten TR, O'Brien CP, et al.American Psychiatric Association; Steering Committee on Practice Guidelines. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry 2007;164 (4 Suppl):5-123.
12. Koob 1988 Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715-723.
13. Kosten 1987 Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?. Arch Gen Psychiatry 1987;44:281-4.
14. Levin 1998 Levin FR, Evans SM, McDowell DM, Kleber. Methylphenidate treatment for cocaine abusers with attention-deficit attention-deficit hyperactivity disorder: a pilot study. Journal of Clinical Psychiatry 1998;59:300-305.
15. Mattick 2003 Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: CD002209]
16. SAMSHA 2004 Substance Abuse and Mental Health Services Administration: Results from the 2003National Survey on Drug Use and Health: National Findings. NSDUH Series H-25.. DHHS Publication (SMA) 04-3964. Rockville, Md, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2004. https://nsduhweb.rti.org [G] 2004.
17. Silagy 2004 Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: CD000146]
18. Volkow 1990 Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, Bendriem B, Christman D, et al.Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 190;147:719-24.
19. Volkow 1996 Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemannn R, Gatley SJ, MacGregor RR, Wolf A. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 1996;14:159- 68.
20. Volkow 1997a Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827-30.
21. Volkow 1997b Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386:830-3.
22. Volkow 2004 Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9:557-69.